NASDAQ:ZEAL - ZEALAND PHARMA/S Stock Price, Forecast & News

ZEALAND PHARMA/S's stock was trading at $28.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ZEAL stock has increased by 4.1% and is now trading at $29.2479. View which stocks have been mosted impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZEALAND PHARMA/S in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ZEALAND PHARMA/S.

ZEALAND PHARMA/S is scheduled to release its next quarterly earnings announcement on Thursday, May 21st 2020. View our earnings forecast for ZEALAND PHARMA/S.

5 Wall Street analysts have issued 1 year target prices for ZEALAND PHARMA/S's shares. Their forecasts range from $38.00 to $42.00. On average, they anticipate ZEALAND PHARMA/S's share price to reach $40.33 in the next year. This suggests a possible upside of 37.9% from the stock's current price. View analysts' price targets for ZEALAND PHARMA/S.

Media headlines about ZEAL stock have trended negative on Sunday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ZEALAND PHARMA/S earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutZEALAND PHARMA/S.

Some companies that are related to ZEALAND PHARMA/S include United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Evotec (EVTCY), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), Zai Lab (ZLAB), Emergent Biosolutions (EBS), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Genmab A/S (GMAB), Ultragenyx Pharmaceutical (RARE) and PPD (SDGR).

Based on aggregate information from My MarketBeat watchlists, some companies that other ZEALAND PHARMA/S investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Ryder System (R), Pandora Media (P), Tandem Diabetes Care (TNDM), Ford Motor (F), Wells Fargo & Co (WFC), NVIDIA (NVDA), Alibaba Group (BABA) and Tesla (TSLA).

(ZEAL) raised $75 million in an IPO on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

ZEALAND PHARMA/S trades on the NASDAQ under the ticker symbol "ZEAL."

ZEALAND PHARMA/S's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.09%), Jane Street Group LLC (0.04%) and Rockefeller Capital Management L.P. (0.03%).

ZEAL stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Rockefeller Capital Management L.P., and Jane Street Group LLC.

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ZEAL stock can currently be purchased for approximately $29.25.

ZEALAND PHARMA/S has a market capitalization of $1.05 billion and generates $6.20 million in revenue each year. The company earns $-85,670,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. ZEALAND PHARMA/S employs 149 workers across the globe. View additional information about ZEALAND PHARMA/S.

The official website for ZEALAND PHARMA/S is http://www.zealandpharma.com/.

ZEALAND PHARMA/S's mailing address is SMEDELAND 36 GLOSTRUP, COPENHAGEN G7, 2600. The company can be reached via phone at 45-8877-3600 or via email at [email protected]